Patterns of drug-induced cardiovascular pathology in the beagle dog: Relevance for humans

Experimental and Toxicologic Pathology

Volumn 50, Issue 4-6, 1998, Pages 283-293

  Greaves, Peter ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Arteries, drug induced pathology; Cardiovascular system, drug induced pathology; Drug induced pathology, cardiovascular system; Myocardium, drug induced pathology

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIAC GLYCOSIDE; CARDIOVASCULAR AGENT; DIGOXIN; ERGOTAMINE DERIVATIVE; HYDRALAZINE; INOTROPIC AGENT; ISOPRENALINE; METHYSERGIDE; MINOXIDIL; NICORANDIL; OXFENICINE; PHOSPHODIESTERASE INHIBITOR; THEOBROMINE; VASOCONSTRICTOR AGENT; VASODILATOR AGENT;

ARTICLE; CARDIOVASCULAR DISEASE; DOG; DRUG INDUCED DISEASE; HEART MUSCLE ISCHEMIA; HEART MUSCLE NECROSIS; HEART VENTRICLE HYPERTROPHY; HEMODYNAMICS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; RISK ASSESSMENT;

EID: 0031708570     PISSN: 09402993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0940-2993(98)80008-0     Document Type: Article

References (65)

1. BACHE RJ, ARENTZEN CE, SIMON AB, VRöBEL TR: Abnormalities in myocardial perfusion during tachycardia in dogs with left ventricular hypertrophy: metabolic evidence for myocardial ischemia. Circulation 1984; 69: 409-417.
2. BAILLIE M: Morbid anatomy of some of the most important parts of the human body, London 1795.
3. BELLIN V, HODGE T, PICAUD P, et al.: The myocardial lesions produced by the potassium channel opener aprikalim in monkeys and rats are prevented by blockade or cardiac β-adrenoceptors. Fund Appl Toxicol 1996; 31: 259-267.
4. BERTENS APM, VAN CAMPEN GJ, MIEX RHM: Thrombosis of the right ventricle in dogs after frequent administration of corticosteroids. Z Versuchstierk 1982; 24: 237-240.
5. BiLLiNGHAM ME (1980): Morphologic changes in drug-induced heart disease. In: BRISTOW MR (ed.): Drug-induced Heart Disease. Elsevier Amsterdam 1980; chap 6 pp 127-149.
6. BLOOR CM, LOWMAN RM: Experimental coronary arteriography. 1. The distribution and extent of allylamineinduced vascular lesions in the dog. Radiology 1963; 81: 770-777.
7. BOOR PJ, HYSMITH RM: Allylamine cardiovascular toxicity. Toxicology 1987; 44: 129-145.
8. BOOR PJ, GOTLIEB AI, JOSEPH EC, et al.: Chemical-induced vascular injury. Toxicol Appl Pharmacol 1995; 132: 177-195.
9. BOURDOIS PS, DANCLA J-L, FACCINI JM, et al.: The subacute toxicology of digoxin in dogs: Clinical chemistry and histopathology of heart and kidneys. Arch Toxicol 1982; 51: 273-283.
10. CARLSON RG, FEENSTRA ES: Toxicologie studies with the hypotensive agent minoxidil. Toxicol Appl Pharmacol 1977; 39: 1-11.
11. CONKIN DJ, BOOR PJ: Allylamine cardiovascular toxicity: Evidence for aberrant vasoreactivity in rats. Toxicol Appl Pharmacol 1998; 148: 245-251.
12. CONNOLLY HM, GRARY JL, McGooN MD, et al.: Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997; 337: 581-588.
13. CONRAD LL, GONZALEZ IE, JOEL W, FURMAN RH: Histochemical evaluation of canine coronary artery and aortic lesions induced by intravenous allylamine. Circulation Res 1956; 4:263-267.
14. CURFMAN GD: Diet pills redux. N Engl J Med 1997; 337: 629-630.
15. DAVIES JNP: Pathology and pathogenesis of endocardial disease. Cardiologia 1963; 42: 161-175.
16. DAVIES MJ, FULTON WFM, ROBERTSON WB: The relationship of coronary thrombosis to ischaemic myocardial necrosis. J Pathol 1979; 127: 99-110.
17. DE BUSK RF, HARRISON DC: The clinical spectrum of papillary muscle disease. N Engl J Med 1969; 281: 1458-1467.
18. DOGTEROM P, ZBINDEN G, REZNIK GK: Cardiotoxicity of vasodilators and positive inotropic/vasodilating drugs in dogs: An overview. CRC Crit Rev Toxicol 1992; 22: 203-241.
19. FEIGL EO: The paradox of adrenergic coronary vasoconstriction. Circulation 1987; 76: 737-745.
20. GANS JH, KORSON R, CATER MR, ACKERLY CC: Effects of short-term and long-term theobromine administration to male dogs. Toxicol Appl Pharmacol 1980; 53: 481-496.
21. GRAHAM JR: Cardiac and pulmonary fibrosis during methysergide therapy for headache. Am J Med Sei 1967; 254: 1-12.
22. GREAVES P, MARTIN J, MICHEL MC, MOMPON P: Cardiac hypertrophy in the dog and rat induced by oxfenicine, an agent which modifies muscle metabolism. Arch Toxicol 1984; Suppl. 7,488-493.
23. GRIFFITH R\V, GRAUWILER J, HODEL CH, et al.: Toxicologie considerations. Ergot Alkaloids and Related Compounds. In: Handbook of Experimental Pharmacology Springer Verlag Berlin 1978; 49: chap. 12, pp 805-851.
24. GRUPP G: Selective updates on mechanisms of action of positive inotropic agents. Mol Cell Biochem 1987; 76: 97-122.
25. HARTMAN HA: Idiopathic extramural coronary arteritis in beagle and mongrel dogs. Vet Pathol 1987; 24: 537-544.
26. HERMAN EH, BALAZS T, YOUNG R, et al.: Acute cardiomyopathy induced by the vasodilating antihypertensive agent minoxidil. Toxicol Appl Pharmacol 1979; 47: 493-503.
27. HIGGINS AJ, FACCINI J, GREAVES P: Coronary hyperemia and cardiac hypertrophy following inhibition of fatty acid oxidation. Evidence of a regulatory role for cytosolic phosphorylation potential. In: DHALLA NS, HEARSE DJ (eds.): Advances in Myocardiology. Plenum Press 1985; vol. 6, 329-338.
28. HOFFMANN K: Toxicology studies with nitrendipine. In: SCRIABINE A, VANOV S, DECK K (eds.): Nitrendipine. Urban und Schwarzenberg Baltimore 1984; chap 3, pp 25-32.
29. ITO K: Carcinostatica auf Vascularendothelien. Yonogo ActaMed 1973; 17: 25-33.
30. JACK D: A way at looking at agonism and antagonism: Lessons from salbutamol, salmeterol and other β-adrenoreceptor agonists. Br J Clin Pharmacol 1991; 31: 501-514.
31. JORIS I, MAJNO G: Medial changes in arterial spasm induced by L-norepinephrine. Am J Pathol 1981; 105: 212-222.
32. KAZDA S, GARTHOFF B, RäMSCH K-D, SCHLüTER G: Nisoldipine. In: New Drugs Annual: Cardiovascular Drugs. Raven Press New York. 1993; pp 243-258.
33. KLINE IK: Myocardial alterations associated with pheochromocytomas. Am J Pathol 1961; 38: 539-551.
34. LEAPELL: Error in medicine. JAM A 1994;272:1851-1857.
35. LIPWORTH BJ, CLARK RA, DHILLON DP, et al.: β-adrenoreceptor responses to high doses of inhaled salbutamol in patients with bronchial asthma. Br J Clin Pharmacol 1988, 26: 527-533.
36. MANSON JE, FAICH GA: Pharmacotherapy for obesity - do the benefits outweigh the risks? N Engl J Med 1996; 335: 659-660.
37. MARCUS ML, CHILIAN WM, KANATSUKA H, et al.: Understanding the coronary circulation through studies at the microvascular level. Circulation 1990; 82: 1-7.
38. MESFIN GM, HIGGINS MJ, ROBINSON FG, ZHONG W-Z: Relationship between serum concentrations, hemodynamic effects, and cardiovascular lesions in dogs treated with minoxidil. Toxicol Appl Pharmacol 1996; 140: 337-344.
39. MESFIN GM, SHAWARYN GG, HIGGINS MJ: Cardiovascular alterations in dogs treated with hydralazine. Toxicol Pathol 1987; 15: 409-416.
40. MESFIN GM, ROBINSON FG, HIGGINS MJ, et al.: The pharmacological basis of the cardiovascular toxicity of minoxidil in the dog. Toxicol Pathol 1995; 23: 498-506.
41. NEMES Z, DIETZ R, MANN JFE, et al.: Vasoconstriction and increased blood pressure in the development of accelerated vascular disease. Virchows Arch [A], 1980; 386: 161-173.
42. PETRUSKA JM, BEATTIE JG, STUART BO, et al.: Cardiovascular effects after inhalation of large doses of albuterol dry powder in rats, monkeys, and dogs: A species comparison. Fund Appl Toxicol 1997; 40: 52-62.
43. REDFIELD MM, NICHOLSON WJ, EDWARDS WD, TAJIK AJ: Valve disease associated with ergot alkaloid use: Echocardiographic and pathologic correlations. Ann Int Med 1992; 117: 50-52.
44. ROBIOLIO PA, RIGOLIN VH, WILSON JS, et al.: Correlation of high serotonin levels with valvular abnormalities detect-ed by cardiac catheterization and echocardiography. Circulation 1995; 92: 790-795.
45. RONA G: Catecholamine cardiotoxicity. J Mol Cell Cardiol 1985; 17: 291-306.
46. RONA G, ZSOTER T, CHAPPEL C, GAUDRY R: Myocardial lesions, circulatory and electrocardiographic changes produced by isoproterenol in the dog. Rev Canad Biol, 1959; 18: 83-94.
47. SANDUSKY GE, MEANS JR, TODD GC: Comparative cardiovascular toxicity in dogs given inotropic agents by continuous intravenous infusion. Toxicol Pathol 1990; 18: 268-278.
48. SCHLüTER G: Toxicological investigations with nimodipine. Arzneim Forsch 1986; 36: 1733-1735.
49. SCHNEIDER P: Hemodynamically induced heart lesions in the dog after administration of cardio-active substances. Exp Pathol 1990; 40: 155-168.
50. SIMONS M, DOWNING SE: Coronary vasoconstriction and catecholamine cardiomyopathy. Am Heart J 1985; 109: 297-304.
51. SMITH CC, ZEEK PM, McGuiRE J: Periarteritis nodosa in experimental hypertensive rats and dogs. Am J Pathol 1944; 20: 721-735.
52. SOBOTA JT, MARTIN WB, CARLSON RG, FEENSTRA ES: Minoxidil: Right atrial cardiac pathology in animals and man. Circulation 1980; 62: 376-387.
53. SOLCIA E, BALLERINI L, BELLINI O, et al.: Cardiomyopathy of doxorubicin in experimental animals. Factors affecting the severity, distribution and evolution of myocardial lesions. Tumori 1981; 67: 461-472.
54. SOLOVEY A, LIN Y, BROWNE P, et al.: Circulating activated endothelial cells in sickle cell anemia. N Engl J Med 1997; 337: 1584-1590.
55. SPENCER A, GREAVES P: Periarteritis in a Beagle colony. J Comp Pathol 1987; 97: 122-128.
56. STAHNKE E: Studien zur Wirkung des Ergotamins. Klin Wschr 1928; 7: 23-25.
57. STEJSKAL V, HAVU N, MALMFORS T: Necrotising vasculitis äs an immunological complication in toxicity study. Arch Toxicol 1982; Suppl. 5, 283-286.
58. STEPANEK J, ZAK F: Zweijährige perorale Applikation von Aminorex am Hund. 2.Teil. Z Kardiol 1975; 64:768-781.
59. SZAKâCS JE, CANNON A: Norepinephrine myocarditis. Am J Clin Pathol 1958; 30: 425-434.
60. TESKE RH, BISHOP SP, RICHTER HF, DETWEILER DK: Subacute digoxin toxicosis in the beagle dog. Toxicol Appl Pharmacol 1976; 35: 283-301.
61. VAN VLEET JF, HERMAN EH, FERRANS VJ: Cardiac morphologic alterations in acute minoxidil cardiotoxicity in miniature swine. Expt Mol Pathol 1984; 41: 10-25.
62. WATERS LL, DESUTO-NAGY GI: Lesions of the coronary arteries and great vessels of the dog following injection of adrenalin. Their prevention by dibenamine. Science 1950; 111: 634-635.
63. WEIR EK, REEVE HL, HUANG JMC, et al.: Anorexic agents aminorex, flenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction. Circulation 1996; 94:2216-2220.
64. WlLENS SL: Enhancement of serum sickness lesions in rabbits with pressor agents. Arch Pathol 1965; 80: 590-603.
65. WILL JA, BISGARD GE: Haemodynamic effects of oral aminnorex and amphetamine in unanaesthetized beagle dogs. Thorax 1972; 27: 120-126.